Practical Application of Insulin Pump Therapy
In Type 2 Diabetes

This activity is an archive of the live session held at the 2009 Fall Managed Care Forum. If you participated in the live activity, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2010 to March 1, 2011
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Medtronic Diabetes/Life Scan Alliance
PLEASE CLICK HERE TO VIEW PRESENTATION

 PLEASE CLICK HERE FOR POST TEST AND EVALUATION

Instructions for CME/CEU: View the presentation, answer the post test, complete the evaluation form and submit to keads@namcp.org.  A score of 70% must be achieved on the post test to receive continuing education credits. You will have the option on the post test/evaluation page to submit your forms electronically or by faxing them to Katie Eads at 804-747-5316.

Description
Insulin pump therapy, or continuous subcutaneous insulin infusion, has become an increasingly popular mode of therapy for patients with type 1 diabetes mellitus. Do the benefits of this type of treatment pertain to type 2 diabetes? This presentation looks at the role of insulin pump therapy in managing type 2 diabetes.

Goal
The goal of this activity is to provide medical directors from plans, purchasers and provider systems and nurse case managers with appropriate education on diabetes and its impact on managed care environments. Participants will be able to:

  • Identify the primary causes of most adult type 2 diabetes

  • Describe why managing glucose levels is the key to leading a healthy lifestyle

  • Describe how insulin therapy can improve patient outcomes

  • Determine appropriate candidates for insulin pump therapy

Faculty: Wendy Lane, MD, Director, Clinical Research, Mountain Diabetes & Endocrine Center

Disclosure:

 Dr. Lane and Mountain Diabetes & Endocrine Center receives research funding from Biodel, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Insulet, MannKind, Medtronic, Novartis, NovoNordisk, and Roche.
  Planning Committee:
 Bill Williams, MD has no real or perceived financial relationships to disclose.
 Katie Eads has no real or perceived financial relationships to disclose.
  NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. NAMCP designates this activity for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses (AAMCN) has been approved as a provider of continuing education by the Virginia Nurses Association (VNA).  VNA is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will be awarded 1.0 contact hours.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
  

This activity is supported by an educational grant from Medtronic Diabetes/Life Scan Alliance
 

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.